Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.50 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.46 |
| ▸ | SORD | Q00796 | 6/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536631 | 1.00 | HRH3 (0.55) | HRH3HRH4ROCK1EIF2AK4SORD | |
| SCHEMBL17626635 | 0.85 | HRH3 (0.60) | HRH3HRH4ROCK1SORD | |
| SCHEMBL25236876 | 0.80 | EIF2AK4 (0.43) | HRH4EIF2AK4SORD | |
| SCHEMBL30457520 | 0.80 | EIF2AK4 (0.43) | HRH4EIF2AK4SORD | |
| SCHEMBL13018663 | 0.80 | HRH3 (0.70) | HRH3HRH4ROCK1 | |
| SCHEMBL27730153 | 0.78 | HRH3 (0.58) | HRH3HRH4ROCK1SORD | |
| SCHEMBL31227206 | 0.78 | HRH3 (0.58) | HRH3HRH4ROCK1SORD | |
| SCHEMBL17626690 | 0.78 | HRH3 (0.63) | HRH3HRH4ROCK1 | |
| SCHEMBL13506774 | 0.77 | HRH3 (0.57) | HRH3HRH4ROCK1 | |
| SCHEMBL30524183 | 0.77 | HRH3 (0.57) | HRH3HRH4ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713978-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-05-11 | — | — | US | disclosed |
| WO-2008089034-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20070238737-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238737-A1 | NOVEL COMPOUNDS | FABP2, VIP, SLC10A2 | HRH3 664/4885HRH4 139/4885ROCK1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.